ReviewExpert opinion on therapeutic targets2025
Identifying protease-activated targets and exploring therapeutic applications.
Review in Expert opinion on therapeutic targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Marine-Derived Proteins: Individual Variability in Health Effects Across Protein Structure, Host Genetics, and Gut Microbiota.Comprehensive reviews in food science and food safety · 2026Review
- PhageScout: Protease Cleavage Site Prediction Using an Experimental Substrate Phage Display Motif-Based Approach.International journal of molecular sciences · 2026Article
- The expanding role of protease therapeutics (2012-2026): from replacement therapies to immune system modulation and beyond.The Biochemical journal · 2026Review
- A Prodrug Strategy to Conditionally Trap Therapeutic Payloads for Improved Tumor Retention.ACS central science · 2026Article
- Development of Cathepsin B‑Activatable Cell-Penetrating Peptides for Tumor Targeting.ACS pharmacology & translational science · 2026Article
- Artificial Multidomain Ribosomally Synthesized and Post-translationally Modified Peptide Enzymes for Farnesylated Peptide Library Generation.ACS synthetic biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
introductionProteases are essential enzymes that regulate protein turnover and activate signaling pathways through targeted peptide bond cleavage. While traditionally regarded as degradative agents, proteases are now recognized for their diverse roles in health and disease, particularly in cancer and viral infections. Advances in high-throughput, mass spectrometry-based technologies have enabled proteome-wide identification of protease substrates, revealing numerous potential therapeutic targets. As large-scale approaches yield expansive substrate lists, it is increasingly important to understand the roles of disease-related proteases within their specific biological contexts. AREAS COVERED: Peptide-level chemical libraries have provided more practical insights, facilitating the development of protease-targeted interventions. However, early efforts to derive inhibitors from these substrates faced challenges due to enzymatic redundancy and substrate promiscuity. Consequently, emerging research has shifted toward harnessing proteolytic activity for conditional activation of therapeutics. Since proteolytic activation can amplify therapeutic effects, protease-activated strategies, such as protease-cleavable linkers in antibody-drug conjugates, have gained interest and are now being applied to other therapeutic modalities. EXPERT OPINION: We believe that identifying substrates activated by disease-associated proteases, enabled by recent technological advances, will lead to deeper biological insights. When combined with peptide-level techniques, these discoveries can drive the development of efficient therapeutic interventions with amplified effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.